Lead text placeholder. Lorem ipsum dolor sit amet, consectetur adipisicing elit.


  • "Phase 1 Study of SL-172154 (SIRP¿-SIRP¿-Fc-CD40L) Administered Intratumorally in Subjects with Cutaneous Squamous Cell Carcinoma or Squamous Cell Carcinoma of the Head and Neck"
  • "Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint, SL-172154 (SIRPa-Fc-CD40L) Administered Intravenously in Subjects with Ovarian Cancer"